However, our report rates for tumour histology (91.2%) and immunohistochemistry (ER/PR: 33.6%, HER2: 31.7%) were higher (tumour histology: 27.8%, ER/PR/HER2: 26%). Here, ERBB2 is linked to neoplasm.